New Delhi, Oct 26 (PTI) Drug firm Lupin today said it hasreceived final approval from the US health regulator to marketits Clonidine Hydrochloride extended release tablets used fortreatment of attention deficit hyperactivity disorder.
The company has received USFDA's final approval to marketthe tablets in the strength of 0.1 mg, Lupin said in a filingto BSE.
The product is generic version of ConcordiaPharmaceuticals Inc's Kapvay extended-release tablets in thesame strength, it added.
As per the IMS MAT June 2017 data, the tablets had annualsales of around USD 66 million in the US, Lupin said.
The tablets are "indicated for the treatment of attentiondeficit hyperactivity disorder (ADHD) as monotherapy or asadjunctive therapy to stimulant medications", it added.
Shares of Lupin ended at Rs 997.10 per scrip, down 0.66per cent from its previous close on BSE today. PTI AKT ADIANU.
This is unedited, unformatted feed from the Press Trust of India wire.
